BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

527 related articles for article (PubMed ID: 1442957)

  • 21. Effects of the antiprogesterone steroid RU 486 during midluteal phase in normal women.
    Schaison G; George M; Lestrat N; Reinberg A; Baulieu EE
    J Clin Endocrinol Metab; 1985 Sep; 61(3):484-9. PubMed ID: 2991322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of levonorgestrel administered in large doses at different stages of the cycle on ovarian function and endometrial morphology.
    Landgren BM; Johannisson E; Aedo AR; Kumar A; Shi YE
    Contraception; 1989 Mar; 39(3):275-89. PubMed ID: 2496951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disruption of follicular maturation and delay of ovulation after administration of the antiprogesterone RU486.
    Liu JH; Garzo G; Morris S; Stuenkel C; Ulmann A; Yen SS
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1135-40. PubMed ID: 2824550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response to intermittent RU486 in women.
    Spitz IM; Croxatto HB; Salvatierra AM; Heikinheimo O
    Fertil Steril; 1993 May; 59(5):971-5. PubMed ID: 8486197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sonographic assessment of ovarian and endometrial changes during long-term Norplant use and their correlation with hormonal levels.
    Shaaban MM; Segal S; Salem HT; Ghaneimah SA; Khalifa EA; Ahmed AG
    Fertil Steril; 1993 May; 59(5):998-1002. PubMed ID: 8486202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of antiprogestin (RU 486) and prostaglandin biosynthesis inhibitor (naproxen) on uterine fluid prostaglandin F2 alpha concentrations.
    Gemzell-Danielsson K; Hamberg M
    Hum Reprod; 1994 Sep; 9(9):1626-30. PubMed ID: 7836511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequential regimen of the antiprogesterone RU486 and synthetic progestin for contraception.
    Kekkonen R; Lähteenmäki P; Luukkainen T; Tuominen J
    Fertil Steril; 1993 Oct; 60(4):610-5. PubMed ID: 8405512
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of ovulation by low-dose mifepristone (RU 486).
    Ledger WL; Sweeting VM; Hillier H; Baird DT
    Hum Reprod; 1992 Aug; 7(7):945-50. PubMed ID: 1331167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute effects of progesterone and the antiprogestin RU 486 on gonadotropin secretion in the follicular phase of the menstrual cycle.
    Permezel JM; Lenton EA; Roberts I; Cooke ID
    J Clin Endocrinol Metab; 1989 May; 68(5):960-5. PubMed ID: 2497130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mifepristone: a potential contraceptive.
    Heikinheimo O; Archer DF
    Clin Obstet Gynecol; 1996 Jun; 39(2):461-8. PubMed ID: 8734010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mode of action of dl-norgestrel and ethinylestradiol combination in postcoital contraception. II. Effect of postovulatory administration on ovarian function and endometrium.
    Ling WY; Wrixon W; Zayid I; Acorn T; Popat R; Wilson E
    Fertil Steril; 1983 Mar; 39(3):292-7. PubMed ID: 6402387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days.
    Csemiczky G; Dieben T; Coeling Bennink HJ; Landgren BM
    Contraception; 1996 Dec; 54(6):333-8. PubMed ID: 8968661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle.
    Croxatto HB; Salvatierra AM; Croxatto HD; Fuentealba B
    Hum Reprod; 1993 Feb; 8(2):201-7. PubMed ID: 8473419
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Late luteal phase administration of RU486 for three successive cycles does not disrupt bleeding patterns or ovulation.
    Croxatto HB; Salvatierra AM; Romero C; Spitz IM
    J Clin Endocrinol Metab; 1987 Dec; 65(6):1272-7. PubMed ID: 3119656
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of anti-progesterones as a medical IUD.
    Nieman LK; Loriaux DL
    Baillieres Clin Obstet Gynaecol; 1988 Sep; 2(3):609-16. PubMed ID: 3233821
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of a single contraceptive Silastic implant containing nomegestrol acetate on ovarian function and cervical mucus production during 2 years.
    Barbosa I; Coutinho E; Hirsch C; Ladipo O; Olsson SE; Ulmsten U
    Fertil Steril; 1996 Apr; 65(4):724-9. PubMed ID: 8654629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of follicular phase administration of mifepristone (RU486) on blastocyst implantation in the rhesus monkey.
    Ghosh D; Nayak NR; Sengupta J
    Contraception; 1997 Aug; 56(2):117-22. PubMed ID: 9315421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Why does RU486 fail to prevent implantation despite success in inducing menstruation?
    Li TC; Lenton EA; Dockery P; Rogers AW; Cooke ID
    Contraception; 1988 Oct; 38(4):401-6. PubMed ID: 3208514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pituitary, ovarian and endometrial effects of progesterone released prematurely during the proliferative phase.
    Shumin X; Johannisson E; Landgren BM; Diczfalusy E
    Contraception; 1983 Feb; 27(2):177-93. PubMed ID: 6851555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.